FDA is interested in improved patient outcomes. So even 15% to 20% coming off ventilators could be compelling for FDA.
Only around 12% normally survive off ventilators. 15% would actually be a 25% improvement in numbers surviving.
https://hotcopper.com.au/threads/msb-trading-2020.5158541/page-8538?post_id=44614786#.XsoB0-QmIlQ
COVID-19 ARDS and ARDS Share Price Scenarios, page-227
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |